Lv4
760 积分 2022-07-20 加入
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
3个月前
已完结
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine
3个月前
已关闭
Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia
4个月前
已完结
Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis
5个月前
已完结
The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors
5个月前
已完结
Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1 Gene Fusion
5个月前
已完结
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
6个月前
已完结
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy
8个月前
已完结
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
8个月前
已完结
Patients with CML in the lymphoid blastic phase have inferior response to anti‐CD19 CAR T‐cell therapy compared to de novo Ph‐positive B cell acute lymphoblastic leukemia
8个月前
已完结
皖公网安备34019202002308
